Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Total search results: 10293 | Ordered by Date (descending)
1 2 3 ... 101 102 103  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
CRISPR Therapeutics–Minapharm: gene transfer technology, 201901– collab + license €na with ProBioGen to develop in vivo delivery technology for CRISPR 2019-01-22
Medison Pharma–Alnylam: RNAi therapeutics, 201901– commcercialisation excl of Onpattro + other RNAi drugs from Alnylam in Israel 2019-01-21
ImaBiotech–Metabrain Research: preclinical research services, 201901– collab strategic partnership ADMET services in preclin metabolic disease models 2019-01-17
ImaBiotech–OCR (FR): preclinical research services, 201901– collab strategic partnership oncology research in pet tumors using bioanalytical imaging 2019-01-17
Miltenyi Biotec–Univ Duisburg-Essen: imaging technology, 201901 acquisition process for opitcal clearing of biological samples for miccrosopy 2019-01-17
Mologen–SEVERAL: credit, 201901–202701 convertible bonds €2.7m at 6% incl existing shareholders 2019-01-17
Mecuris–Bavaria (govt): investment, 201901 financing round Series A totalling €3.6m incl existing investor Bayern Kapital GmbH 2019-01-16
Mecuris–High-Tech Gründerfonds: investment, 201901 financing round Series A totalling €3.6m incl existing investor HTGF 2019-01-16
Mecuris–Mulcan: investment, 201901 financing round Series A totalling €3.6m incl new investor MII Mulcan International Investments GmbH 2019-01-16
Mecuris–OTHER: investment, 201901 financing round Series A totalling €3.6m incl new investor one of largest German hospital chains 2019-01-16
Mecuris–SEVERAL: investment, 201901 financing round Series A €3.6m incl Bayern Kapital + HTGF + Vesalius Biocapital + Mulcan et al. 2019-01-16
Mecuris–Vesalius Biocapital: investment, 201901 financing round Series A totalling €3.6m incl new investor Vesalius Biocapital III SICAR 2019-01-16
Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners 2019-01-16
Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later 2019-01-16
InterAx Biotech–Falcon III Ventures: investment, 201901 financing round totalling CHF3m incl co-lead investor Falcon III Ventures 2019-01-15
InterAx Biotech–SEVERAL: investment, 201901 financing round CHF3m led by Falcon III Ventures + Investiere 2019-01-15
InterAx Biotech–Verve Capital Partners: investment, 201901 financing round totalling CHF3m incl co-lead investor Investiere 2019-01-15
Sanofi–Biomunex: antibody technology, 201901– license €na to use BiXAb technology to generate + develop bi- + multi-specific antibodies 2019-01-15
ATUM–Solentim: cell line development technology, 201901– collab product integration of VIPS hardware + Leap-In Transposase expression technology 2019-01-14
Cell Signaling Technology–Omni Life Science: cell research instruments, 201901– distribution of OLS’ CERO + CESY instruments by Bioké in Benelux 2019-01-14
Solentim–Sciad Communications: public relations, 201901 service existent by Sciad 2019-01-14
Affimed–JPMorgan Chase: investor conference, 201901 supply service Affimed presents at JP Morgan Healthcare Conference 2019 2019-01-10
Chronomics–SEVERAL: investment, 201901 seed financing round £1.12m from Anthemis + SOSV 2019-01-10
Evotec–JPMorgan Chase: investor conference, 201901 supply service Evotec presents at JP Morgan Healthcare Conference 2019 2019-01-10
Samplix–EU (govt): grant, 201901– Horizon 2020 SME Instrument Program Grant €1.9m 2019-01-10
Tecan–JPMorgan Chase: investor conference, 201901 supply service Tecan Group presents at JP Morgan Healthcare Conference 2019 2019-01-10
UroGen–JPMorgan Chase: investor conference, 201901 supply service UroGen Pharma presents at JP Morgan Healthcare Conference 2019 2019-01-10
Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins 2019-01-09
BC Platforms–MedEngine (FI): medical data science services, 201901– collab strategic partnership to provide solutions for pharma + health sectors 2019-01-09
Denali Therapeutics–Sirion Biotech: gene delivery technology, 201901– license + collab develop AAV vectors for CNS diseases that could cross BBB 2019-01-09
Galapagos–JPMorgan Chase: investor conference, 201901 supply service Galapagos presents at JP Morgan Healthcare Conference 2019 2019-01-09
Orchard Therapeutics–JPMorgan Chase: investor conference, 201901 supply service Orchard presents at JP Morgan Healthcare Conference 2019 2019-01-09
Senolytic Therapeutics–Life Biosciences: investment, 201901 acquisition of Senolytic by Life Biosciences 2019-01-09
Exscientia–Celgene: investment, 201901 financing round Series B totalling $26m incl new investor Celgene Corp 2019-01-07
Exscientia–Evotec: investment, 201901 financing round Series B totalling $26m incl $6m from existing investor Evotec AG 2019-01-07
Exscientia–GT Healthcare Capital Partners: investment, 201901 financing round Series B totalling $26m incl new investor GT Healthcare Capital Partners 2019-01-07
Exscientia–SEVERAL: investment, 201901 financing round Series B $26m incl Celgene Corp + GT Heallthcare Capital Partners + Evotec 2019-01-07
F2G Ltd–Optimum Strategic Communications: public relations, 201901 service existent by Optimum 2019-01-07
Keros Therapeutics–SEVERAL: investment, 201901 financing round Series B $23m incl Pontifax + Arkin Bioventures + Partners Innovation Fund 2019-01-07
Loxo Oncology–Lilly: investment, 201901– acquisition cash tender offer $8b for $235/share 2019-01-07
N-of-One–Qiagen: investment, 201901 acquisition €na of N-of-One Inc by Qiagen 2019-01-07
Medigene–Helmholtz: cell therapy, 201901– license to co-stimulator to enhance TCR therapies for solid tumours from HMGU 2019-01-04
Ribon Therapeutics–Celgene: investment, 201901 financing round Series B totalling $65m incl new + co-investor Celgene Corp 2019-01-04
Ribon Therapeutics–Column Group: investment, 201901 financing round Series B totalling $65m incl existing + co-investor The Column Group 2019-01-04
Ribon Therapeutics–Deerfield Management: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Deerfield Management 2019-01-04
Ribon Therapeutics–Euclidean Capital: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Euclidean Capital 2019-01-04
Ribon Therapeutics–JnJ: investment, 201901 financing round Series B totalling $65m incl new + co-investorJJDC 2019-01-04
Ribon Therapeutics–Novartis: investment, 201901 financing round Series B totalling $65m incl new + lead investor Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Osage Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Osage University Partners 2019-01-04
Ribon Therapeutics–SEVERAL: investment, 201901 financing round Series B $65m led by Novartis Venture Fund 2019-01-04
Ribon Therapeutics–Takeda: investment, 201901 financing round Series B totalling $65m incl existing + co-investor Takeda Ventures 2019-01-04
Ribon Therapeutics–US Venture Partners: investment, 201901 financing round Series B totalling $65m incl existing + co-investor US Venture Partners 2019-01-04
Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo 2019-01-04
Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital 2019-01-04
Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation 2019-01-04
Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners 2019-01-04
Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP 2019-01-04
Atriva Therapeutics–High-Tech Gründerfonds: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–MC Services: public relations, 201901 service existent by MC Services 2019-01-03
Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Celgene–BMS: investment, 201901– acquisition merger $74b in cash + shares with BMS owners owning 69% + Celgene owners 31% post-closing ANNOUNCED 2019-01-03
Fujifilm–Zyme Communications: public relations, 201901 service existent for Fujifilm Irvine Scientific by Zyme 2019-01-02
Minervax–Novo Group: investment, 2018 investment €3.6m by Novo REPAIR Impact Fund 2018-12-31
Procarta Biosystems–Novo Group: investment, 2018 investment €1.5m by Novo REPAIR Impact Fund 2018-12-31
Harpoon Therapeutics–SEVERAL: investment, 201812– IPO $86m FILED 2018-12-27
Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS 2018-12-24
Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners 2018-12-24
Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation 2018-12-24
Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management 2018-12-24
Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health 2018-12-24
Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital 2018-12-24
Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech 2018-12-24
Nabriva–Hercules Technology: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital 2018-12-21
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
Morphogen-IX–Cambridge Innovation Capital: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor CIC 2018-12-20
Morphogen-IX–Medicxi Ventures: investment, 201812 financing round Series B totalling £18.4m incl existing + lead investor Medicxi 2018-12-20
Morphogen-IX–SEVERAL: investment, 201812 financing round Series B £18.4m ($23.2m) led by Medicxi + incl CIC + Cambridge Enterprise 2018-12-20
Morphogen-IX–Univ Cambridge: investment, 201812 financing round Series B totalling £18.4m incl existing + co-investor Cambridge Enterprise 2018-12-20
Altheia Science–SEVERAL: investment, 201812 financing round Series A final closing €7.7m ($8.3m) bringing total round to €17m ($19.3m) 2018-12-19
Annexon Biosciences–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Annexon Biosciences–SEVERAL: investment, 201812 financing round Series C $75m led by new investor Bain Capital Life Sciences 2018-12-19
Cellestia Biotech–PPF Group: investment, 201812 financing round Series A totalling CHF20m incl existing + co-lead investor Sotio/PPF Group 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
PreOmics–High-Tech Gründerfonds: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–Think.Health Ventures: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
Carmat–EU (govt): credit, 201812– EFSI €30m loan from EIB to move artificial heart towards marketing 2018-12-17
Seer–Invus Group: investment, –201812 financing rounds Series A + B totalling $36m incl Series B lead investor Invus 2018-12-17
Seer–Maverick Ventures: investment, –201812 financing rounds Series A + B totalling $36m incl Series A lead investor Maverick Ventures 2018-12-17
Seer–SEVERAL: investment, –201812 financing rounds Series A + B of $36m until 12/18 as company emerges from stealth 2018-12-17
Kurma–France (govt): investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–Idinvest Partners: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–NewCap: public relations, 201812 service existent by NewCap 2018-12-14
Kurma–Servier: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest 2018-12-14
Kurma–SEVERAL: investment, 201812 first closing of Kurma Biofund III with target for final closing of €150m 2018-12-14
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
1 2 3 ... 101 102 103  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top